Biology Reference
In-Depth Information
triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.
Biochem J 333:139-149
Houslay MD (2001) Intracellular targeting and regulation of PDE4 cAMP specific Phosphodies-
terases. Prog Nucleic Acid Res Mol Biol 69:249-315
Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP
breakdown. Trends Biochem Sci 35:91-100
Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orches-
trate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18
Houslay MD, Adams DR (2010) Lockdown on phosphodiesterase-4. Nat Biotechnol 28:38-40
Houslay MD, Schafer P, Zhang K (2005) Keynote review: phosphodiesterase-4 as a therapeutic
target. Drug Discov Today 10:1503-1519
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-specific phosphodiesterase-4 enzymes in the
cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signal-
ing. Circ Res 100:950-966
Huai Q, Wang H, Sun Y, Kim HY, Liu Y, Ke H (2003) Three-dimensional structures of PDE4D in
complex with roliprams and implication on inhibitor selectivity. Structure 11:865-873
Huai Q, Wang H, Zhang W, Colman RW, Robinson H, Ke H (2004) Crystal structure of
phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine
binding. Proc Natl Acad Sci USA 101(26):9624-9629
Huang D, Hinds TR, Martinez SE, Doneanu C, Beavo JA (2004) Molecular determinants of cGMP
binding to chicken cone photoreceptor phosphodiesterase. J Biol Chem 279:48143-48151
Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD (1996)
The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in
transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct
kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344
Huston E, Houslay TM, Baillie GS, Houslay MD (2006) cAMP phosphodiesterase-4A1 (PDE4A1)
has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that
underpins compartmentalized cAMP signalling. Biochem Soc Trans 34:504-509
Huston E, Lynch M, Mohamed A, Collins DM, Hill EV, MacLeod R, Krause E, Baillie GS,
Houslay MD (2008) EPAC and PKA allow cAMP dual control over DNA-PK nuclear
translocation. Proc Natl Acad Sci USA 105:12791-12796
Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional
domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic
activity and rolipram binding. Mol Pharmacol 50:891-899
Jarvest RL, Lowe G, Baraniak J, Stec WJ (1982) A stereochemical investigation of the hydrolysis of
cyclic AMP and the (Sp)-and (Rp)-diastereoisomers of adenosine cyclic 3
0
:5
0
-phosphorothioate
by bovine heart and baker's-yeast cyclic AMP phosphodiesterases. Biochem J 203:461-470
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C (2010)
Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-
independent mechanism. Proc Natl Acad Sci USA 107:9795-9800
Jin SL, Swinnen JV, Conti M (1992) Characterization of the structure of a lowKm, rolipram-sensitive
cAMP phosphodiesterase. Mapping of the catalytic domain. J Biol Chem 267:18929-18939
Jin SC, Richard FJ, Kuo WP, D'Ercole AJ, Conti M (1999) Impaired growth and fertility of
cAMP-specific phosphodiesterase PDE4D- deficient mice. Proc Natl Acad Sci USA 96:
11998-12003
Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, Beavo JA (1997) A subset of olfactory
neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl
cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA
94:3388-3395
Kalgutkar AS, Choo E, Taylor TJ, Marfat A (2004) Disposition of CP-671, 305, a selective
phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica 34:755-770
Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F (2003) Cilostazol as a unique
antithrombotic agent. Curr Pharm Des 9:2289-2302
